| . | All patients (4600 pts) . | Derivation (4172 pts) . | Validation (428 pts) . | P-value . |
|---|---|---|---|---|
| Age, yrs | 74.1 ± 9.4 | 74.1 ± 9.4 | 74.2 ± 9.2 | .691 |
| Male sex, % | 65.4 | 65.7 | 62.4 | .187 |
| BMI, kg/m2 | 25.9 ± 4.4 | 25.9 ± 4.3 | 25.7 ± 4.8 | .191 |
| Arterial hypertension, % | 77.4 | 76.8 | 82.9 | .005 |
| Diabetes mellitus, % | 32.5 | 33.4 | 24.3 | <.001 |
| Hx of CAD, % | 58.2 | 57.0 | 69.2 | <.001 |
| Hx of COPD, % | 18.2 | 18.3 | 16.4 | .343 |
| Hx of Atrial fibrillation, % | 61.2 | 60.4 | 68.9 | <.001 |
| eGFR, mL/min | 50.1 ± 23.0 | 49.9 ± 23.1 | 51.1 ± 22.4 | .254 |
| Haemoglobin, g/dL | 12.2 ± 1.9 | 12.2 ± 1.8 | 12.3 ± 1.9 | .230 |
| NT-proBNP, pg/mL | 6490 ± 12 661 | 6532 ± 13 139 | 6123 ± 7284 | .223 |
| NYHA functional class, % | .200 | |||
| I | 0.7 | 0.4 | 3.0 | |
| II | 12.6 | 12.5 | 13.8 | |
| III | 68.5 | 69.1 | 62.9 | |
| IV | 18.2 | 18.0 | 20.3 | |
| Medication, % | ||||
| Beta-blocker | 74.5 | 72.6 | 88.8 | <.001 |
| RAS inhibitor | 76.8 | 76.2 | 82.2 | .005 |
| Mineralocorticoid receptor blocker | 49.6 | 49.9 | 45.9 | .105 |
| Triple GDMT, % | 32.7 | 32.2 | 37.0 | .047 |
| EuroScore II, % | 8.7 ± 8.0 | 8.3 ± 7.5 | 10.0 ± 9.9 | .010 |
| . | All patients (4600 pts) . | Derivation (4172 pts) . | Validation (428 pts) . | P-value . |
|---|---|---|---|---|
| Age, yrs | 74.1 ± 9.4 | 74.1 ± 9.4 | 74.2 ± 9.2 | .691 |
| Male sex, % | 65.4 | 65.7 | 62.4 | .187 |
| BMI, kg/m2 | 25.9 ± 4.4 | 25.9 ± 4.3 | 25.7 ± 4.8 | .191 |
| Arterial hypertension, % | 77.4 | 76.8 | 82.9 | .005 |
| Diabetes mellitus, % | 32.5 | 33.4 | 24.3 | <.001 |
| Hx of CAD, % | 58.2 | 57.0 | 69.2 | <.001 |
| Hx of COPD, % | 18.2 | 18.3 | 16.4 | .343 |
| Hx of Atrial fibrillation, % | 61.2 | 60.4 | 68.9 | <.001 |
| eGFR, mL/min | 50.1 ± 23.0 | 49.9 ± 23.1 | 51.1 ± 22.4 | .254 |
| Haemoglobin, g/dL | 12.2 ± 1.9 | 12.2 ± 1.8 | 12.3 ± 1.9 | .230 |
| NT-proBNP, pg/mL | 6490 ± 12 661 | 6532 ± 13 139 | 6123 ± 7284 | .223 |
| NYHA functional class, % | .200 | |||
| I | 0.7 | 0.4 | 3.0 | |
| II | 12.6 | 12.5 | 13.8 | |
| III | 68.5 | 69.1 | 62.9 | |
| IV | 18.2 | 18.0 | 20.3 | |
| Medication, % | ||||
| Beta-blocker | 74.5 | 72.6 | 88.8 | <.001 |
| RAS inhibitor | 76.8 | 76.2 | 82.2 | .005 |
| Mineralocorticoid receptor blocker | 49.6 | 49.9 | 45.9 | .105 |
| Triple GDMT, % | 32.7 | 32.2 | 37.0 | .047 |
| EuroScore II, % | 8.7 ± 8.0 | 8.3 ± 7.5 | 10.0 ± 9.9 | .010 |
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; GDMT, guideline directed medical therapy; NYHA, New York Heart Association; RAAS, renin–angiotensin–aldosterone-system.
| . | All patients (4600 pts) . | Derivation (4172 pts) . | Validation (428 pts) . | P-value . |
|---|---|---|---|---|
| Age, yrs | 74.1 ± 9.4 | 74.1 ± 9.4 | 74.2 ± 9.2 | .691 |
| Male sex, % | 65.4 | 65.7 | 62.4 | .187 |
| BMI, kg/m2 | 25.9 ± 4.4 | 25.9 ± 4.3 | 25.7 ± 4.8 | .191 |
| Arterial hypertension, % | 77.4 | 76.8 | 82.9 | .005 |
| Diabetes mellitus, % | 32.5 | 33.4 | 24.3 | <.001 |
| Hx of CAD, % | 58.2 | 57.0 | 69.2 | <.001 |
| Hx of COPD, % | 18.2 | 18.3 | 16.4 | .343 |
| Hx of Atrial fibrillation, % | 61.2 | 60.4 | 68.9 | <.001 |
| eGFR, mL/min | 50.1 ± 23.0 | 49.9 ± 23.1 | 51.1 ± 22.4 | .254 |
| Haemoglobin, g/dL | 12.2 ± 1.9 | 12.2 ± 1.8 | 12.3 ± 1.9 | .230 |
| NT-proBNP, pg/mL | 6490 ± 12 661 | 6532 ± 13 139 | 6123 ± 7284 | .223 |
| NYHA functional class, % | .200 | |||
| I | 0.7 | 0.4 | 3.0 | |
| II | 12.6 | 12.5 | 13.8 | |
| III | 68.5 | 69.1 | 62.9 | |
| IV | 18.2 | 18.0 | 20.3 | |
| Medication, % | ||||
| Beta-blocker | 74.5 | 72.6 | 88.8 | <.001 |
| RAS inhibitor | 76.8 | 76.2 | 82.2 | .005 |
| Mineralocorticoid receptor blocker | 49.6 | 49.9 | 45.9 | .105 |
| Triple GDMT, % | 32.7 | 32.2 | 37.0 | .047 |
| EuroScore II, % | 8.7 ± 8.0 | 8.3 ± 7.5 | 10.0 ± 9.9 | .010 |
| . | All patients (4600 pts) . | Derivation (4172 pts) . | Validation (428 pts) . | P-value . |
|---|---|---|---|---|
| Age, yrs | 74.1 ± 9.4 | 74.1 ± 9.4 | 74.2 ± 9.2 | .691 |
| Male sex, % | 65.4 | 65.7 | 62.4 | .187 |
| BMI, kg/m2 | 25.9 ± 4.4 | 25.9 ± 4.3 | 25.7 ± 4.8 | .191 |
| Arterial hypertension, % | 77.4 | 76.8 | 82.9 | .005 |
| Diabetes mellitus, % | 32.5 | 33.4 | 24.3 | <.001 |
| Hx of CAD, % | 58.2 | 57.0 | 69.2 | <.001 |
| Hx of COPD, % | 18.2 | 18.3 | 16.4 | .343 |
| Hx of Atrial fibrillation, % | 61.2 | 60.4 | 68.9 | <.001 |
| eGFR, mL/min | 50.1 ± 23.0 | 49.9 ± 23.1 | 51.1 ± 22.4 | .254 |
| Haemoglobin, g/dL | 12.2 ± 1.9 | 12.2 ± 1.8 | 12.3 ± 1.9 | .230 |
| NT-proBNP, pg/mL | 6490 ± 12 661 | 6532 ± 13 139 | 6123 ± 7284 | .223 |
| NYHA functional class, % | .200 | |||
| I | 0.7 | 0.4 | 3.0 | |
| II | 12.6 | 12.5 | 13.8 | |
| III | 68.5 | 69.1 | 62.9 | |
| IV | 18.2 | 18.0 | 20.3 | |
| Medication, % | ||||
| Beta-blocker | 74.5 | 72.6 | 88.8 | <.001 |
| RAS inhibitor | 76.8 | 76.2 | 82.2 | .005 |
| Mineralocorticoid receptor blocker | 49.6 | 49.9 | 45.9 | .105 |
| Triple GDMT, % | 32.7 | 32.2 | 37.0 | .047 |
| EuroScore II, % | 8.7 ± 8.0 | 8.3 ± 7.5 | 10.0 ± 9.9 | .010 |
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; GDMT, guideline directed medical therapy; NYHA, New York Heart Association; RAAS, renin–angiotensin–aldosterone-system.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
